Alvotech (ALVO)
NASDAQ: ALVO · Real-Time Price · USD
12.28
+0.58 (4.96%)
At close: Feb 21, 2025, 4:00 PM
12.48
+0.20 (1.63%)
After-hours: Feb 21, 2025, 6:06 PM EST
Alvotech Revenue
Alvotech had revenue of $102.99M in the quarter ending September 30, 2024, with 478.60% growth. This brings the company's revenue in the last twelve months to $393.92M, up 517.92% year-over-year. In the year 2023, Alvotech had annual revenue of $93.38M with 9.84% growth.
Revenue (ttm)
$393.92M
Revenue Growth
+517.92%
P/S Ratio
7.89
Revenue / Employee
$394,313
Employees
999
Market Cap
3.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 93.38M | 8.37M | 9.84% |
| Dec 31, 2022 | 85.02M | 45.33M | 114.23% |
| Dec 31, 2021 | 39.68M | -29.77M | -42.86% |
| Dec 31, 2020 | 69.45M | -13.23M | -16.00% |
| Dec 31, 2019 | 82.68M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
ALVO News
- 1 day ago - Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara - Reuters
- 1 day ago - Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S. - GlobeNewsWire
- 4 days ago - FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea - Investopedia
- 4 days ago - Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) - GlobeNewsWire
- 26 days ago - Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab) - GlobeNewsWire
- 2 months ago - Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024 - GlobeNewsWire
- 3 months ago - Alvotech's Position In The Coming Biosimilar Gold Rush - Seeking Alpha
- 3 months ago - Certain Closed-end Funds Advised by Franklin Templeton Fund Adviser, LLC Announce Appointment of New Chair and Directors - Business Wire